OSBP | Jotup

Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients

Retrieved on:

星期一, 一月 8, 2024

Blood pressure, Bradycardia, Risk, Orchestra, Collection, Consultant, Hypertension, Mortality, Disease, HOPE, Stroke, Comorbidity, Patient, Safety, Heart failure, Beat (music), BioMed Central, OSBP, Pharmaceutical industry

AVIM therapy is an investigational patented bioelectronic therapy, administered using a standard dual-chamber pacemaker, designed to immediately, substantially and persistently reduce blood pressure.

Key Points:

AVIM therapy is an investigational patented bioelectronic therapy, administered using a standard dual-chamber pacemaker, designed to immediately, substantially and persistently reduce blood pressure.
Orchestra BioMed and Medtronic, Inc. (NYSE: MDT) (“Medtronic”) formed a strategic collaboration for the development and commercialization of AVIM therapy for hypertensive pacemaker patients in July 2022.
Orchestra BioMed is actively screening patients for enrollment in the BACKBEAT pivotal study.
The study will randomize approximately 500 patients 1:1 to AVIM therapy combined with continued medical therapy (treatment) or continued medical therapy and standard pacing alone (control).

Waterfront Technical Services, a Sentar Company, Wins NASA Marshall Space Flight Center Small Business Subcontractor of the Year

Retrieved on:

星期二, 十一月 7, 2023

Sentar Inc. (Sentar), a women-owned small business specializing in advanced cyber intelligence solutions and technology, announced today Waterfront Technical Services (Waterfront), a Sentar company, has been awarded the NASA Marshall Space Flight Center (MSFC) Small Business Subcontractor of the Year.

Key Points:

Sentar Inc. (Sentar), a women-owned small business specializing in advanced cyber intelligence solutions and technology, announced today Waterfront Technical Services (Waterfront), a Sentar company, has been awarded the NASA Marshall Space Flight Center (MSFC) Small Business Subcontractor of the Year.
This award qualifies Waterfront for the Agency-Level NASA Small Business Industry Awards (SBIA), facilitated by the NASA Office of Small Business Programs (OSBP), which will be announced in early 2024.
Waterfront performs a variety of critical functions in support of MSFC missions and programs including flight and ground operations, data center operations, information technology, software development, and test supporting NASA’s spaceflight missions.
“We are honored to be recognized as the NASA Marshall Space Flight Center Small Business Subcontractor of the Year," said Allan McCaleb, Director of Civil Space Programs at Sentar.

Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

Retrieved on:

星期二, 九月 19, 2023

Orchestra BioMed and Medtronic plc (NYSE: MDT) formed a strategic collaboration for the development and commercialization of AVIM therapy for hypertensive pacemaker patients in July 2022.

Key Points:

Orchestra BioMed and Medtronic plc (NYSE: MDT) formed a strategic collaboration for the development and commercialization of AVIM therapy for hypertensive pacemaker patients in July 2022.
Under the collaboration, Medtronic is providing Orchestra BioMed with development, clinical, and regulatory support for the BACKBEAT global pivotal study, which Orchestra BioMed is sponsoring.
Orchestra BioMed will share in the revenues generated from Medtronic sales of the AVIM-enabled pacing systems.
“We are thrilled to receive IDE approval from the FDA and move forward with plans to initiate the BACKBEAT global pivotal study, which is designed to support potential future regulatory review and potential approval of AVIM therapy for hypertensive patients indicated for a pacemaker.

EuroPCR 2023 | 6 Month Outcome of the SMART Study: satisfactory BP control achieved with reduced medication burden

Retrieved on:

星期五, 五月 19, 2023

Late, Feedback, RCT, Sympathetic, Research, RDN, Hypertension, BP, OSBP, Patient, Denervation, 24 Hours, SMART, Treatment, Pharmaceutical industry

It demonstrates that msRDN can effectively control blood pressure while greatly reducing the dosage of antihypertensive drugs.

Key Points:

It demonstrates that msRDN can effectively control blood pressure while greatly reducing the dosage of antihypertensive drugs.
In the 6 months follow-up with a strict drug regimen, the msRDN group demonstrated effective blood pressure control.
OSBP control rate of the msRDN group was 95% with significantly reduced drug burden compared to the sham group.
The result is a resounding prove that patients in the msRDN group can achieve satisfactory BP control with markedly lower anti-hypertensive drug dosage.

NeoSystems Joins Forces with Native Hawaiian Organizations Association to Support Local Government Contractors

Retrieved on:

星期四, 四月 13, 2023

HONOLULU, April 13, 2023 /PRNewswire/ -- NeoSystems, a full-service strategic outsourcer, IT systems integrator and managed services provider to the government contracting market, has joined forces with the Native Hawaiian Organizations Association (NHOA), a local trade organization dedicated to the long-term success of the federal contracting community in Hawaii. Sponsored in part by NeoSystems, the two-day 2023 Small Business Summit will feature educational workshops and networking opportunities to increase the competitiveness of local businesses in gaining government contracting work, a substantial part of the state's economy. It will be held at the Ala Moana Hotel in Honolulu on April 18 and 19.

Key Points:

"We want to ensure every business who desires to work with the federal government is prepared to do so.
At NHOA, we deliver a full spectrum of support services that culminate in our annual conference made possible in part through the support of sponsors like NeoSystems."
Highlights of Day1 of the conference, include:
Legal and regulatory updates from the U.S. Small Business Association by John Klein and Mark Hagedorn.
NeoSystems will sponsor the pre-conference evening reception on April 17 from 5:30 to 8:30 p.m. at the scenic Ho'okupu Center.

CQG Announces Additional Connectivity to China Derivatives Markets via Esunny

Retrieved on:

星期二, 十月 18, 2022

CHICAGO and HONG KONG, Oct. 18, 2022 /PRNewswire/ -- CQG, a leading global provider of high-performance technology solutions for traders, brokers, commercial hedgers and exchanges, announced today that it is providing additional connectivity into China's commodity exchanges via Esunny International (HK) Co., Limited (Esunny), the leading Chinese trading platform provider and a wholly owned subsidiary of the Zhengzhou Commodity Exchange.

Key Points:

To better serve a growing list of Overseas Special Broker Participants (OSBP), as well as fulfilling other futures brokerage and clearing firms' requirements, CQG has further enhanced its connectivity to China markets by integrating with Esunny.
Rick Chang, General Manager of CQG Greater China, said: "Esunny is one of the major pillars that drives the China commodity market to function dynamically from a technological perspective not only domestically but also with the international trading community.
Esunny's core mission of enabling more international participants to trade China markets aligns seamlessly with CQG's mission in China.
CQG is headquartered in Denver, with 16 sales and support offices and data centers in key markets globally.

CQG Announces Additional Connectivity to China Derivatives Markets via Esunny

Retrieved on:

星期二, 十月 18, 2022

CHICAGO and HONG KONG, Oct. 17, 2022 /PRNewswire/ -- CQG, a leading global provider of high-performance technology solutions for traders, brokers, commercial hedgers and exchanges, announced today that it is providing additional connectivity into China's commodity exchanges via Esunny International (HK) Co., Limited (Esunny), the leading Chinese trading platform provider and a wholly owned subsidiary of the Zhengzhou Commodity Exchange.

Key Points:

To better serve a growing list of Overseas Special Broker Participants (OSBP), as well as fulfilling other futures brokerage and clearing firms' requirements, CQG has further enhanced its connectivity to China markets by integrating with Esunny.
The initiative particularly supports business models operated by Hong Kong and Singapore futures commission merchants (FCMs) focused on facilitating trades into China.
Rick Chang, General Manager of CQG Greater China, said: "Esunny is one of the major pillars that drives the China commodity market to function dynamically from a technological perspective not only domestically but also with the international trading community.
Esunny's core mission of enabling more international participants to trade China markets aligns seamlessly with CQG's mission in China.

TCT 2022: SYMPLICITY HTN-3 trial data show sustained long-term blood pressure reductions with Medtronic renal denervation procedure

Retrieved on:

星期日, 九月 18, 2022

Observation, RDN, RF, Blood pressure, NYSE, Risk, Hospital, Hypertension, Stroke, Patient, Medtronic, OSBP, Harvard Medical School, Research, TCT, Brigham and Women's Hospital, Pharmaceutical industry, Lancet, Medicine

Subjects who underwent radiofrequency renal denervation (RF RDN) with the first generation Symplicity renal denervation system, had a statistically significant reduction in office and ambulatory blood pressure compared to subjects in the sham control group.

Key Points:

Subjects who underwent radiofrequency renal denervation (RF RDN) with the first generation Symplicity renal denervation system, had a statistically significant reduction in office and ambulatory blood pressure compared to subjects in the sham control group.
The results illustrate that for certain patients with high blood pressure, despite attempts to adhere to multiple medications and modify their lifestyles, their blood pressure remains poorly controlled, putting them at risk for cardiovascular complications such as stroke."
A total of 535 patients with treatment resistant hypertension were randomized 2:1 to RDN (n=364) vs. sham control (n=171).
This latest analysis of the SYMPLICITY HTN-3 trial examined the long-term safety and efficacy of RDN in hypertensive patients who were on antihypertensive medications and received treatment with the Symplicity blood pressure procedure.

Orchestra BioMed™ Announces Presentations at TCT 2021 of Positive Long-Term Clinical Results from the MODERATO II Study Showing the Significant Clinical Impact of BackBeat CNT™ on Isolated Systolic Hypertension and Pulse Pressure

Retrieved on:

星期五, 十一月 5, 2021

HOPE, Population, TCT, Hypertension, Beat (music), Mercury (element), ISH, NEW, OSBP, Hemodynamics, Patient, Pulse pressure, Research, GLOBE, Moyamoya disease, CNT, Heart failure, Pharmaceutical industry

NEW HOPE, Pa., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Orchestra BioMed™, Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company focused on developing transformative therapeutic products for large unmet clinical needs in procedure-based medicine, today announced multiple presentations of long-term clinical results and ISH subgroup data from the MODERATO II study of BackBeat Cardiac Neuromodulation Therapy™ (BackBeat CNT™) in patients with hypertension and an indication for a pacemaker at the Transcatheter Cardiovascular Therapeutics (TCT) 2021 annual conference being held in-person in Orlando, Florida, and virtually from November 4 – 6, 2021.

Key Points:

Results showed a mean reduction of 17.5 mmHg in office systolic blood pressure (oSBP) among all BackBeat CNT treated patients who completed 24-month follow-up.
Further, in patients with ISH, BackBeat CNT drove statistically significant reductions of 9.4 mmHg in ambulatory Pulse Pressure and 13.3 mmHg in office Pulse Pressure at 6 months as compared to control patients.
There was a significant reduction in ambulatory Pulse Pressure of 9.4 mmHg in BackBeat CNT treated patients at 6 months vs. control (p=0.01).
We are excited by BackBeat CNTs significant and durable impact on blood pressure in the MODERATO II study, said David Hochman, chairman and CEO of Orchestra BioMed.

Stellar Solutions Wins NASA 2020 Small Business Industry Award

Retrieved on:

星期四, 十月 7, 2021

PALO ALTO, Calif., Oct. 7, 2021 /PRNewswire-PRWeb/ -- Stellar Solutions, the global aerospace engineering company, has won a NASA 2020 Small Business Industry Award in the category of the Center-Level Small Business Prime Contractor of the Year.

Key Points:

PALO ALTO, Calif., Oct. 7, 2021 /PRNewswire-PRWeb/ -- Stellar Solutions, the global aerospace engineering company, has won a NASA 2020 Small Business Industry Award in the category of the Center-Level Small Business Prime Contractor of the Year.
The award recognizes Stellar Solutions' work at NASA Headquarters to support the Human Exploration and Operations Mission Directorate's Human Landing System (HLS) acquisition and Space Technology Mission Directorate's Lunar Surface Innovation Initiative.
About the NASA Small Business Awards and Achievement: The NASA Office of Small Business Programs recognizes civil servant and industry achievement in, and in support of, the Agency's Small Business Program each fiscal year.
https://osbp.nasa.gov/award.html
About Stellar Solutions, Inc.: Stellar Solutions is a global aerospace and systems engineering services provider to commercial, defense, intelligence, civil and international sectors.